Adia Nutrition Reports 146% Revenue Increase in Q1 2026, Despite Net Loss

Adia Nutrition, Inc. reported a significant increase in revenue for the first quarter of 2026, generating $176,275 compared to $71,764 in the same period of 2025, marking a 146% increase year-over-year. The revenue growth was primarily driven by medical procedures, which accounted for $104,850, and sales of biologics, which contributed $69,775. The company reported a gross profit of $67,577, up from $14,052 in the prior year, despite an increase in the cost of revenue from $57,712 to $108,698.

The company's operating expenses also rose, totaling $219,497 for the first quarter of 2026, compared to $124,596 in the previous year. This increase was attributed to higher legal and professional fees, which surged to $78,809 from $47,814, and increased advertising and promotion costs, which rose to $37,007 from $21,522. As a result, Adia Nutrition recorded a net loss of $162,525 for the quarter, compared to a net loss of $116,219 in the first quarter of 2025.

In terms of operational developments, Adia Nutrition has made strategic moves to enhance its market position. The company has focused on expanding its healthcare services, particularly in Autologous Hematopoietic Stem Cell Transplantation (AHSCT) treatments for Multiple Sclerosis patients. Additionally, Adia Nutrition has engaged in acquisitions, including the purchase of Biolete, LLC, and an 18% equity stake in Cement Factory, LLC, which are expected to bolster its product offerings and market reach.

As of March 31, 2026, Adia Nutrition's total assets increased to $776,868 from $594,826 at the end of 2025, driven by a rise in current assets, particularly accounts receivable and inventory. The company reported a total liability of $1,197,067, up from $852,500, largely due to an increase in accounts payable and deferred revenue. The accumulated deficit also widened to $16,136,007, raising concerns about the company's ability to continue as a going concern without generating sufficient revenue or securing additional capital.

Looking ahead, Adia Nutrition aims to leverage its line of credit and ongoing fundraising efforts to support its operational needs and growth initiatives. Management anticipates continued revenue growth and plans to maintain a focus on strategic partnerships and product development to enhance its market presence. However, the company acknowledges the risks associated with its financial position and the need for effective capital management to ensure sustainability in the competitive healthcare landscape.